Home
About Us
Membership
Member Biography

Member Biography

Jennifer King, MD

Jennifer King, M.D.

Phone: (317) 944-0920, Patient issues/appointments

Faculty appointments

Assistant Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Associate member, Experimental and Developmental Therapeutics

A phase II trial evaluating the efficacy of Cabozantinib in the treatment of incurable patients with refractory germ cell tumorsCTO-IUSCCC-0752

Neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer with selective bladder sparingCTO-HCRN-GU20-444

Retrospective Analysis of Patients with Urothelial Carcinoma at Indiana University: 1990-2033 IUSCCC-0835

First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumorsCTO-BNT142-01

Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumorCTO-IUSCCC-0894

A Phase II Open-Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based ImmunotherapyCTO-IMMU132-06

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)CTO-HCRN-GU22-587

PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]CTO-A031704

#ResearchCuresCancer

Support Our Research